Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer
NCT04230954 is a phase 2 interventional trial sponsored by University of South Alabama. As of 21 Nov 2026, it was terminated. It studies Cabozantinib and Pembrolizumab in Cervical Cancer, Metastatic Cervical Cancer and 2 more conditions. The registry lists an enrollment of 5 participants at 1 site in 1 country. The registry lists a start date of 16 Apr 2020 and a primary completion date of 16 Feb 2022.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT04230954 |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional trial |
| Lead sponsor | University of South Alabama |
| Enrollment | 5 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Cervical Cancer, Metastatic Cervical Cancer, Persistent Cervical Cancer and Recurrent Cervical Cancer |
| Drugs | Cabozantinib and Pembrolizumab |
| Start | 16 Apr 2020 |
| Primary completion | 16 Feb 2022 |
| Study completion | 16 Feb 2022 |
| Last update posted | 7 Jun 2022 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Stefanie White
University of South Alabama
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of South Alabama Mitchell Cancer Institute
Mobile
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT04230954
Each answer restates registry values shown on this page.
What is NCT04230954?
NCT04230954 is a phase 2 interventional trial sponsored by University of South Alabama. It studies Cabozantinib and Pembrolizumab in Cervical Cancer, Metastatic Cervical Cancer and 2 more conditions.
Who leads NCT04230954?
The registry names Stefanie White (study director, University of South Alabama) as the overall official.
Where does NCT04230954 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT04230954 study?
The registered drug and biological interventions are Cabozantinib and Pembrolizumab.
When did NCT04230954 end?
The registry lists a primary completion date of 16 Feb 2022 and a study completion date of 16 Feb 2022. The sponsor last updated the record on 7 Jun 2022.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.